Antibody-drug conjugate payloads

Methods in Molecular Biology

Volumn 1045, Issue , 2013, Pages 51-70

  Anderl, Jan ^a   Faulstich, Heinz ^a   Hechler, Torsten ^a   Kulke, Michael ^a  

^a Wilex Biotechnology GmbH   (Germany)

Author keywords

Amanitin; Amatoxin; Auristatin; Calicheamicin; DM1; DM4; Maytansine; MMAE; MMAF; Payload

Indexed keywords

AMANITIN; ANTIBIOTIC C 1027; ANTIBODY CONJUGATE; ANTINEOPLASTIC ANTIBIOTIC; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; DOLASTATIN 10; DOLASTATIN 15; DYNEMICIN; ENEDIYNE; ESPERAMICIN; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; KEDARCIDIN; MADUROPEPTIN; MAYTANSINE; MONOCLONAL ANTIBODY; NAMENAMICIN; RNA POLYMERASE II; SHISHIJIMICIN; SOBLIDOTIN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VEDOTIN; VINBLASTINE; ZINOSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DIARRHEA; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA CELL; NAUSEA; NEUROTOXICITY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; WEAKNESS;

EID: 84934436340     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_4     Document Type: Article

References (111)

1. Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12:278-287
2. Steiner M, Neri D (2011) Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends. Clin Cancer Res 17:6406-6416
3. Kreitman RJ, Pastan I (2011) Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 17:6398-6405
4. Choudhary S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16:495-503
5. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169
6. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240
7. Chari RVJ (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
8. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147-159
9. SedlacekHH,SeemannG,HoffmannD(1992) Antibodies as carriers of cytotoxicity, 1st edn. S. Karger Publishing, Basel, Switzerland
10. Tolcher AW (2000) BR96-doxorubicin: Been there, done that! J Clin Oncol 18:4000
11. Saleh MN, Sugarman S, Murray J et al (2000) Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol 18:2282-2292
12. Tolcher AW, Sugarman S, Gelmon KA et al (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17:478-484
13. Laguzza BC, Nichols CL, Briggs SL et al (1989) New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. J Med Chem 32:548-555
14. Apelgren LD, Zimmerman DL, Briggs SL et al (1990) Antitumor activity of themonoclonal antibody-vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer. Cancer Res 50: 3540-3544
15. Petersen BH, DeHerdt SV, Schneck DW et al (1991) The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res 51:2286-2290
16. Uadia P, Blair AH, Ghose T (1984) Tumor and tissue distribution of a methotrexate-Anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Res 44:4263-4266
17. Kulkarni PN, Blair AH, Ghose T et al (1985) Conjugation ofmethotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo. Cancer Immunol Immunother 19:211-214
18. Elias DJ, Kline LE, Robbins BA et al (1994) Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med 150:1114-1122
19. LoRusso PM,WeissD,GuardinoE et al (2011) Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437-6447
20. Guha M (2012) T-DM1 impresses at ASCO. Nat Biotechnol 30:728
21. Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631-637
22. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 17:6417-6427
23. Vetter J (1998) Toxins of amanita phalloides. Toxicon 36:13-24
24. Safavy A, Bonner JA, Waksal HWet al (2003) Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 14:302-310
25. Ojima I (2008) Guided molecular missiles for tumor-targeting chemotherapy -case studies using the second-generation taxoids as warheads. Acc Chem Res 41:108-119
26. Chari RV, Jackel KA, Bourret LA et al (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res 55:4079-4084
27. Zhao RY, Erickson HK, Leece BA et al (2012) Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. J Med Chem 55:766-782
28. Beck A, Lambert J, Sun M et al. (2012) Fourth world antibody-drug conjugate summit: Feb 29-Mar 1 2012, Frankfurt, Germany. MAbs 4
29. Kupchan SM, Komoda Y, Court WA et al (1972) Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 94:1354-1356
30. Kupchan SM, Komoda Y, Branfman AR et al (1977) The maytansinoids. Isolation, structural elucidation, and chemical interrelation of novel ansa macrolides. J Org Chem 42:2349-2357
31. Rinehart KL, Shield LS (1976) Chemistry of the ansamycin antibiotics. Fortschr Chem Org Naturst 33:231-307
32. Cassady JM, Chan KK, Floss HG et al (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52:1-26
33. Remillard S, Rebhun LI, Howie GA et al (1975) Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002-1005
34. Mandelbaum-Shavit F, Wolpert-DeFilippes MK, Johns DG (1976) Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 72:47-54
35. Bhattacharyya B, Wolff J (1977) Maytansine binding to the vinblastine sites of tubulin. FEBS Lett 75:159-162
36. Ravry MJ, Omura GA, Birch R (1985) Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. Am J Clin Oncol 8:148-150
37. Issell BF, Crooke ST (1978) Maytansine. Cancer Treat Rev 5:199-207
38. Chari RV, Martell BA, Gross JL et al (1992) Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131
39. Widdison WC, Wilhelm SD, Cavanagh EE et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
40. Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
41. Austin CD, Wen X, Gazzard L et al (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A 102:17987-17992
42. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5:543-549
43. Helft PR, Schilsky RL, Hoke FJ et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10:4363-4368
44. Tijink BM, Buter J, de Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12:6064-6072
45. Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 21:211-222
46. Kovtun YV, Audette CA, Ye Y et al (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214-3221
47. Chari RV (1998) Targeted delivery of chemotherapeutics: Tumor-Activated prodrug therapy. Adv Drug Deliv Rev 31:89-104
48. Hollander I, Kunz A, Hamann PR (2008) Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem 19:358-361
49. Takeshita A, Shinjo K, Yamakage N et al (2009) CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 146:34-43
50. Szakács G, Paterson JK, Ludwig JA et al (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234
51. Zhao RY,Wilhelm SD, Audette C et al (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 54:3606-3623
52. Pettit GR, Kamano Y, Fujii Y et al (1981) Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod 44:482-485
53. Pettit GR, Kamano Y, Brown P et al (1982) Antineoplastic agents. 3. Structure of the cyclic peptide dolastatin 3 from Dolabella auricularia. J Am Chem Soc 104:905-907
54. Pettit GR, Kamano Y, Holzapfel CW et al (1987) Antineoplastic agents. 150. The structure and synthesis of dolastatin 3. J Am Chem Soc 109:7581-7582
55. Pettit GR, Kamano Y, Herald CL et al (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. JAmChem Soc 109:6883-6885
56. Pettit GR, Kamano Y, Herald CL et al (1993) Isolation of dolastatins 10-15 from the marine mollusc Dolabella auricularia. Tetrahedron 49:9151-9170
57. Pettit GR, Kamano Y, Kizu H et al (1989) Isolation and structure of the cell growth inhibitory depsipeptides dolastatins 11 and 12. Heterocycles 28:553-558
58. Pettit GR, Kamano Y, Herald CL et al (1989) Antineoplastic agent. 174. Isolation and structure of the cytostatic depsipeptide dolastatin 13 from the sea hare Dolabella auricularia. J Am Chem Soc 111:5015-5017
59. Pettit GR, Kamano Y, Herald CL et al (1990) Antineoplastic agents. 190. Isolation and structure of the cyclodepsipeptide dolastatin 14. J Org Chem 55:2989-2990
60. Pettit GR, Kamano Y, Dufresne C et al (1989) Isolation and structure of the cytostatic linear depsipeptide dolastatin 15. J Org Chem 54:6005-6006
61. Quentmeier H, Brauer S, Pettit GR et al (1992) Cytostatic effects of dolastatin 10 and dolastatin 15 on human leukemia cell lines. Leuk Lymphoma 6:245-250
62. Steube KG, Grunicke D, Pietsch T et al (1992) Dolastatin 10 and dolastatin 15: Effects of two natural peptides on growth and differentiation of leukemia cells. Leukemia 6:1048-1053
63. Bai R, Pettit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39:1941-1949
64. Bai R, Pettit GR, Hamel E (1990) Structureactivity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10. Biochem Pharmacol 40:1859-1864
65. Bai R, Roach MC, Jayaram SK et al (1993) Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 45:1503-1515
66. Bai R, Friedman SJ, Pettit GR et al (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol 43:2637-2645
67. Pitot HC, McElroy EA, Reid JM et al (1999) Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 5:525-531
68. Banerjee S, Wang Z, Mohammad M et al (2008) Efficacy of selected natural products as therapeutic agents against cancer. J Nat Prod 71:492-496
69. Kobayashi M, Natsume T, Tamaoki S et al (1997) Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88:316-327
70. Riely GJ, Gadgeel S, Rothman I et al (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55:181-185
71. Patel S, Keohan ML, Saif MW et al (2006) Phase II study of intravenous TZT-1027 in patients with advanced or metastatic softtissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 107:2881-2887
72. Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
73. Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
74. Anon (2011) Brentuximab vedotin: Adis R&D profile. Drugs R&D 11:85-95
75. Agensys Inc. (2012) A study to assess the safety, pharmacokinetics and effectiveness of AGS-16C3F monotherapy in subjects with renal cell carcinoma (RCC) of clear cell or papillary histology. ClinicalTrials.gov, NCT01672775
76. Seattle Genetics Inc. (2009) A phase 1 doseescalation trial of SGN-75 in CD70-positive non-Hodgkin lymphoma or renal cell carcinoma. ClinicalTrials.gov, NCT01015911
77. Lee MD, Dunne TS, Chang CC et al (1987) Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calichemicin. gamma.1I. J Am Chem Soc 109:3466-3468
78. Lee MD, Dunne TS, Siegel MM et al (1987) Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin.gamma.1I. J Am Chem Soc 109:3464-3466
79. Maiese WM, Lechevalier MP, Lechevalier HA et al (1989) Calicheamicins, a novel family of antitumor antibiotics: Taxonomy, fermentation and biological properties. J Antibiot 42:558-563
80. Golik J, Clardy J, Dubay G et al (1987) Esperamicins, a novel class of potent antitumor antibiotics. 2. Structure of esperamicin X. J Am Chem Soc 109:3461-3462
81. Golik J, Dubay G, Groenewold G et al (1987) Esperamicins, a novel class of potent antitumor antibiotics. 3. Structures of esperamicins A1, A2, and A1b. J Am Chem Soc 109:3462-3464
82. Edo K, Akiyama-Murai Y, Saito K et al (1988) Hydrogen bromide adduct of neocarzinostatin chromophore: One of the stable derivatives of native neocarzinostatin chromophore. J Antibiot 41:1272-1274
83. Smith AL, Nicolaou KC (1996) The enediyne antibiotics. J Med Chem 39:2103-2117
84. McDonald LA, Capson TL, Krishnamurthy G et al (1996) Namenamicin, a new enediyne antitumor antibiotic from the marine ascidian Polysyncraton lithostrotum. J Am Chem Soc 118:10898-10899
85. Oku N, Matsunaga S, Fusetani N (2003) Shishijimicins A-C, novel enediyne antitumor antibiotics from the ascidian Didemnum proliferum1. J Am Chem Soc 125: 2044-2045
86. Lee MD, Dunne TS, Chang CC et al (1992) Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins. beta.1Br, gamma.1Br, alpha.2I, alpha.3I, beta.1I, gamma.1I, and.delta.1I. J Am Chem Soc 114:985-997
87. Zein N, Poncin M, Nilakantan R et al (1989) Calicheamicin gamma 1I and DNA: Molecular recognition process responsible for sitespecificity. Science 244:697-699
88. Zein N, Sinha AM, McGahren WJ et al (1988) Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201
89. De Voss JJ, Townsend CA, Ding WD et al (1990) Site-specific atom transfer from DNA to a bound ligand defines the geometry of a DNA-calicheamicin.gamma.1I complex. J Am Chem Soc 112:9669-9670
90. Mah SC, Townsend CA, Tullius TD (1994) Hydroxyl radical footprinting of calicheamicin. Relationship of DNA binding to cleavage. Biochemistry 33:614-621
91. Ellestad GA (2011) Structural and conformational features relevant to the anti-tumor activity of calicheamicin γ 1I. Chirality 23:660-671
92. Hinman LM, Hamann PR, Wallace R et al (1993) Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res 53:3336-3342
93. Gillespie AM, Broadhead TJ, Chan SY et al (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol 11:735-741
94. Chan SY, Gordon AN, Coleman RE et al (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother 52:243-248
95. Naito K, Takeshita A, Shigeno K et al (2000) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14:1436-1443
96. Nabhan C, Rundhaugen L, Jatoi M et al (2004) Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease. Ann Oncol 15:1231-1236
97. Kantarjian H, Thomas D, Jorgensen J et al (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 13:403-411
98. Letschert K, Faulstich H, Keller D et al (2006) Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci 91:140-149
99. Wieland T (1986) Peptides of poisonous amanita mushrooms, 1st edn. Springer, New York
100. Fiume L, Stirpe F (1966) Decreased RNA content in mouse liver nuclei after intoxication with α-Amanitin. Biochim Biophys Acta 123:643-645
101. Lindell TJ, Weinberg F, Morris PW et al (1970) Specific inhibition of nuclear RNA polymerase II by alpha-Amanitin. Science 170:447-449
102. Kedinger C, Gniazdowski M, Mandel JL et al (1970) Alpha-Amanitin: A specific inhibitor of one of two DNA-pendent RNA polymerase activities from calf thymus. Biochem Biophys Res Commun 38:165-171
103. Meihlac M, Kedinger C, Chambon P et al (1970) Amanitin binding to calf thymus RNA polymerase B. FEBS Lett 9:258-260
104. Cochet-Meilhac M, Nuret P, Courvalin JC et al (1974) Animal DNA-dependent RNA polymerases 12. Determination of the cellular number of RNA polymerase B molecules. Biochim Biophys Acta 353:185-192
105. Bushnell DA, Cramer P, Kornberg RD (2002) Structural basis of transcription: Alpha-Amanitin-RNA polymerase II cocrystal at 2.8 A resolution. Proc Natl Acad Sci U S A 99:1218-1222
106. Barbanti-Brodano G, Fiume L (1973) Selective killing of macrophages by amanitin-Albumin conjugates. Nat New Biol 243:281-283
107. Danielczyk A, Stahn R, Faulstich D et al (2006) PankoMab: A potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother 55:1337-1347
108. Moldenhauer G, Salnikov AV, Luttgau S et al (2012) Therapeutic potential of amanitinconjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104:622-634
109. Anderl J, Mueller C, Heckl-Oestreicher B. et al. (2011) Highly potent antibodyamanitin conjugates cause tumor-selective apoptosis. AACR 102nd Annual Meeting Abstract# 3616
110. Baumann K, Zanotti G, Faulstich H (1994) A beta-turn in alpha-Amanitin is the most important structural feature for binding to RNA polymerase II and three monoclonal antibodies. Protein Sci 3:750-756
111. Faulstich H, Fauser U (1978) The course of amanita intoxication in beagle dogs. In: Amanita toxins and poisoning. Gerhard Witzstrock, Baden-Baden, pp 115-123